{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:47:07Z","timestamp":1792403227815,"version":"4.4.0"},"reference-count":147,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Approximately 5\u201310% of all breast cancer (BC) cases are caused by germline pathogenic variants (GPVs) in various cancer predisposition genes (CPGs). The most common contributors to hereditary BC are BRCA1 and BRCA2, which are associated with hereditary breast and ovarian cancer (HBOC). ATM, BARD1, CHEK2, PALB2, RAD51C, and RAD51D have also been recognized as CPGs with a high to moderate risk of BC. Primary and secondary cancer prevention strategies have been established for HBOC patients; however, optimal preventive strategies for most hereditary BCs have not yet been established. Most BC-associated CPGs participate in DNA damage repair pathways and cell cycle checkpoint mechanisms, and function jointly in such cascades; therefore, a fundamental understanding of the disease drivers in such cascades can facilitate the accurate estimation of the genetic risk of developing BC and the selection of appropriate preventive and therapeutic strategies to manage hereditary BCs. Herein, we review the functions of key BC-associated CPGs and strategies for the clinical management in individuals harboring the GPVs of such genes.<\/jats:p>","DOI":"10.3390\/ijms23137481","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T10:21:33Z","timestamp":1657016493000},"page":"7481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-9158","authenticated-orcid":false,"given":"Akiyo","family":"Yoshimura","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4150-7938","authenticated-orcid":false,"given":"Issei","family":"Imoto","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jamaoncol.2020.2134","article-title":"Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"6","author":"Silvestri","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jjco\/hyv088","article-title":"Cancer incidence and incidence rates in Japan in 2009: A study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project","volume":"45","author":"Hori","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-015-3628-4","article-title":"Active and passive smoking and risk of breast cancer: A meta-analysis","volume":"154","author":"Macacu","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Oze, I., Ito, H., Kasugai, Y., Yamaji, T., Kijima, Y., Ugai, T., Kasuga, Y., Ouellette, T.K., Taniyama, Y., and Koyanagi, Y.N. (2021). A Personal Breast Cancer Risk Stratification Model Using Common Variants and Environmental Risk Factors in Japanese Females. Cancers, 13.","DOI":"10.3390\/cancers13153796"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"djv042","DOI":"10.1093\/jnci\/djv042","article-title":"Twenty-five years of breast cancer risk models and their applications","volume":"107","author":"Gail","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4247-z","article-title":"Breast cancer risk models: A comprehensive overview of existing models, validation, and clinical applications","volume":"164","author":"Braun","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00439-013-1299-y","article-title":"The complex genetic landscape of familial breast cancer","volume":"132","author":"Melchor","year":"2013","journal-title":"Hum. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc.2016.72","article-title":"Hereditary breast and ovarian cancer: New genes in confined pathways","volume":"16","author":"Nielsen","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ruscito, I., Gasparri, M.L., De Marco, M.P., Costanzi, F., Besharat, A.R., Papadia, A., Kuehn, T., Gentilini, O.D., Bellati, F., and Caserta, D. (2021). The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13061391"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A Population-Based Study of Genes Previously Implicated in Breast Cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6384190","DOI":"10.1155\/2020\/6384190","article-title":"Secondary Prevention in Hereditary Breast and\/or Ovarian Cancer Syndromes Other Than BRCA","volume":"2020","author":"Piombino","year":"2020","journal-title":"J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Neiger, H.E., Siegler, E.L., and Shi, Y. (2021). Breast Cancer Predisposition Genes and Synthetic Lethality. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115614"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/32918","article-title":"E-cadherin germline mutations in familial gastric cancer","volume":"392","author":"Guilford","year":"1998","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ng0597-64","article-title":"Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome","volume":"16","author":"Liaw","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/34432","article-title":"A serine\/threonine kinase gene defective in Peutz-Jeghers syndrome","volume":"391","author":"Hemminki","year":"1998","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4939-6716-2_13","article-title":"Detection and Characterization of R Loop Structures","volume":"1543","author":"Soler","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1093\/nar\/gkab151","article-title":"Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies","volume":"49","author":"Stok","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10147-017-1182-2","article-title":"BRCA1 gene: Function and deficiency","volume":"23","author":"Takaoka","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Creeden, J.F., Nanavaty, N.S., Einloth, K.R., Gillman, C.E., Stanbery, L., Hamouda, D.M., Dworkin, L., and Nemunaitis, J. (2021). Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08863-9"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2020.00301","article-title":"Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/abbs\/gmx055","article-title":"Cell cycle-dependent control of homologous recombination","volume":"49","author":"Zhao","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12575-020-00133-5","article-title":"Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: Review of radiosensitivity assays","volume":"22","author":"Sadeghi","year":"2020","journal-title":"Biol. Proced. Online"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: Statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-pathol-012615-044446","article-title":"Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies","volume":"11","author":"Lee","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10371","article-title":"BRCA1 tumour suppression occurs via heterochromatin-mediated silencing","volume":"477","author":"Zhu","year":"2011","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.15252\/emmm.201708194","article-title":"Thwarting endogenous stress: BRCA protects against aldehyde toxicity","volume":"9","author":"Nussenzweig","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cell.2017.05.010","article-title":"A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability","volume":"169","author":"Tan","year":"2017","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.15252\/emmm.201607446","article-title":"BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity","volume":"9","author":"Tacconi","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s41388-018-0535-2","article-title":"PALB2 connects BRCA1 and BRCA2 in the G2\/M checkpoint response","volume":"38","author":"Simhadri","year":"2019","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cell.2018.08.056","article-title":"Human Rad52 Promotes XPG-Mediated R-loop Processing to Initiate Transcription-Associated Homologous Recombination Repair","volume":"175","author":"Yasuhara","year":"2018","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102668","DOI":"10.1016\/j.dnarep.2019.102668","article-title":"How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?","volume":"81","author":"Venkitaraman","year":"2019","journal-title":"DNA Repair"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15908","DOI":"10.1038\/ncomms15908","article-title":"Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/bcr938","article-title":"The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer","volume":"6","author":"Allred","year":"2004","journal-title":"Breast Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.7150\/jca.30588","article-title":"Estradiol and Progesterone Induced Differentiation and Increased Stemness Gene Expression of Human Fallopian Tube Epithelial Cells","volume":"10","author":"Chang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"670392","DOI":"10.3389\/fcell.2021.670392","article-title":"Replication Fork Reversal and Protection","volume":"9","author":"Qiu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nature11676","article-title":"Recombination-restarted replication makes inverted chromosome fusions at inverted repeats","volume":"493","author":"Mizuno","year":"2013","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1363-4","article-title":"Isomerization of BRCA1-BARD1 promotes replication fork protection","volume":"571","author":"Starowicz","year":"2019","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E10642","DOI":"10.1073\/pnas.1803177115","article-title":"BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes","volume":"115","author":"Sasanuma","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cell.2009.11.030","article-title":"Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer","volume":"139","author":"Lin","year":"2009","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1093\/nar\/gkz262","article-title":"BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells","volume":"47","author":"Chiang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nm0809-842","article-title":"Mammary development meets cancer genomics","volume":"15","author":"Prat","year":"2009","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/jnci\/djz079","article-title":"Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program","volume":"112","author":"Chiarelli","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.18632\/oncotarget.22733","article-title":"Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer","volume":"8","author":"Hirasawa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: Systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/bjc.2012.483","article-title":"The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers","volume":"107","author":"Iqbal","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2018.05.035","article-title":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance","volume":"155","author":"Canto","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100589","DOI":"10.1016\/j.blre.2019.100589","article-title":"Genotype-phenotype associations in Fanconi anemia: A literature review","volume":"37","author":"Giri","year":"2019","journal-title":"Blood Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review","volume":"22","author":"Li","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis","volume":"136","author":"Rookus","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/annonc\/mdt134","article-title":"Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: A prospective analysis","volume":"24","author":"Jager","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10549-013-2765-x","article-title":"Risk-reducing surgery increases survival in BRCA1\/2 mutation carriers unaffected at time of family referral","volume":"142","author":"Ingham","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_65","first-page":"Cd012464","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12282-015-0619-6","article-title":"Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: A meta-analysis","volume":"22","author":"Xu","year":"2015","journal-title":"Breast Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nm.4118","article-title":"RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers","volume":"22","author":"Nolan","year":"2016","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-016-4029-z","article-title":"Can we prevent BRCA1-associated breast cancer by RANKL inhibition?","volume":"161","author":"Kotsopoulos","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_69","first-page":"1169","article-title":"The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells","volume":"22","author":"Fedier","year":"2003","journal-title":"Int. J. Oncol."},{"key":"ref_70","first-page":"845","article-title":"Dominant-negative activity of a Brca1 truncation mutant: Effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line","volume":"20","author":"Sylvain","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Nakamura, S., Aoki, D., and Miki, Y. (2021). Hereditary Breast and Ovarian Cancer, Springer.","DOI":"10.1007\/978-981-16-4521-1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/sj.onc.1204812","article-title":"Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway","volume":"20","author":"Lafarge","year":"2001","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2011.35.2682","article-title":"Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience","volume":"29","author":"Arun","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1158\/0008-5472.CAN-13-1443","article-title":"Compensatory functions and interdependency of the DNA-binding domain of BRCA2 with the BRCA1-PALB2-BRCA2 complex","volume":"74","author":"Dejsuphong","year":"2014","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1158\/1078-0432.CCR-06-1269","article-title":"Targeting the double-strand DNA break repair pathway as a therapeutic strategy","volume":"12","author":"Lord","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers with HER2-Negative Breast Cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13053-019-0111-y","article-title":"The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers-systematic review and meta-analysis","volume":"17","author":"Caramelo","year":"2019","journal-title":"Hered. Cancer Clin. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/annonc\/mdy209","article-title":"Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_82","unstructured":"Safonov, A., Bandlamudi, C., de Lara, P., Ferraro, E., Derakhshan, F., Will, M., Donoghue, M., Selenica, P., Drago, J., and Rosen, E. (2021, January 13). BRCA2 Linked to Inferior Outcomes of Treatment with CDK4\/6 Inhibitors Plus Endocrine Therapy. Proceedings of the SABCS 2021, San Antonio, TX, USA."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bruno, L., Ostinelli, A., Waisberg, F., Enrico, D., Ponce, C., Rivero, S., Blanco, A., Zarba, M., Loza, M., and Fabiano, V. (2022). Cyclin-Dependent Kinase 4\/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. JCO Precis. Oncol., 6.","DOI":"10.1200\/PO.21.00140"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/bjc.2016.41","article-title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","volume":"114","author":"Drew","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2017.36","article-title":"A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours","volume":"116","author":"Wilson","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-021-00240-w","article-title":"Cisplatin +\/\u2212 rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer","volume":"7","author":"Kalra","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant Talazoparib for Patients with Operable Breast Cancer With a Germline BRCA Pathogenic Variant","volume":"38","author":"Litton","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: Randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"Xia","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","article-title":"A recurrent mutation in PALB2 in Finnish cancer families","volume":"446","author":"Erkko","year":"2007","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Nepomuceno, T.C., De Gregoriis, G., de Oliveira, F.M.B., Suarez-Kurtz, G., Monteiro, A.N., and Carvalho, M.A. (2017). The Role of PALB2 in the DNA Damage Response and Cancer Predisposition. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091886"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tibs.2018.10.008","article-title":"The Tumor Suppressor PALB2: Inside Out","volume":"44","author":"Ducy","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10689-020-00163-8","article-title":"Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer","volume":"19","author":"Toh","year":"2020","journal-title":"Fam. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated with Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-10-0893","article-title":"Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer","volume":"10","author":"Villarroel","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00258","article-title":"Association of Germline PALB2 Mutation and Response to Platinum-Based Chemotherapy in Metastatic Breast Cancer: A Case Series","volume":"2","author":"Isaac","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2019.37.15_suppl.3006","article-title":"Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes","volume":"37","author":"Gruber","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00018-019-03365-1","article-title":"Structural basis of homologous recombination","volume":"77","author":"Sun","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.7792600","article-title":"A single ataxia telangiectasia gene with a product similar to PI-3 kinase","volume":"268","author":"Savitsky","year":"1995","journal-title":"Science"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0165-4608(96)00328-7","article-title":"Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer","volume":"92","author":"Athma","year":"1996","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/sj.onc.1203444","article-title":"Ionizing radiation activates the ATM kinase throughout the cell cycle","volume":"19","author":"Pandita","year":"2000","journal-title":"Oncogene"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/gepi.21971","article-title":"Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk","volume":"40","author":"Marabelli","year":"2016","journal-title":"Genet. Epidemiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cge.12710","article-title":"Health risks for ataxia-telangiectasia mutated heterozygotes: A systematic review, meta-analysis and evidence-based guideline","volume":"90","author":"Roeleveld","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Putti, S., Giovinazzo, A., Merolle, M., Falchetti, M.L., and Pellegrini, M. (2021). ATM Kinase Dead: From Ataxia Telangiectasia Syndrome to Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215498"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/2159-8290.CD-16-1179","article-title":"Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4\/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer","volume":"7","author":"Haricharan","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1158\/1078-0432.CCR-17-3702","article-title":"Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers","volume":"24","author":"Anurag","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"580251","DOI":"10.3389\/fphar.2020.580251","article-title":"Mechanisms of CDK4\/6 Inhibitor Resistance in Luminal Breast Cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, Double-Blind Phase II Trial with Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.radonc.2004.07.010","article-title":"Breast cancer in female carriers of ATM gene alterations: Outcome of adjuvant radiotherapy","volume":"72","author":"Meyer","year":"2004","journal-title":"Radiother. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ijrobp.2021.01.045","article-title":"ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations","volume":"110","author":"McDuff","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10549-016-3912-y","article-title":"Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: A retrospective cohort study","volume":"158","author":"Narayan","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","article-title":"Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome","volume":"286","author":"Bell","year":"1999","journal-title":"Science"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/BCTT.S111394","article-title":"Current perspectives on CHEK2 mutations in breast cancer","volume":"9","author":"Apostolou","year":"2017","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ijc.20073","article-title":"Limited relevance of the CHEK2 gene in hereditary breast cancer","volume":"110","author":"Dufault","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Klijn","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Toss, A., Tenedini, E., Piombino, C., Venturelli, M., Marchi, I., Gasparini, E., Barbieri, E., Razzaboni, E., Domati, F., and Caggia, F. (2021). Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers. Genes, 12.","DOI":"10.3390\/genes12050616"},{"key":"ref_136","first-page":"227","article-title":"Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes","volume":"13","author":"Menes","year":"2020","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/bcr3147","article-title":"Low expression levels of ATM may substitute for CHEK2\/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer","volume":"14","author":"Knappskog","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00432-015-1981-7","article-title":"Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers","volume":"141","author":"Kriege","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Cimmino, F., Formicola, D., and Capasso, M. (2017). Dualistic Role of BARD1 in Cancer. Genes, 8.","DOI":"10.3390\/genes8120375"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ng1296-430","article-title":"Identification of a RING protein that can interact in vivo with the BRCA1 gene product","volume":"14","author":"Wu","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Alenezi, W.M., Fierheller, C.T., Recio, N., and Tonin, P.N. (2020). Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes, 11.","DOI":"10.3390\/genes11080856"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0968-0004(98)01232-8","article-title":"Role of the human RAD51 protein in homologous recombination and double-stranded-break repair","volume":"23","author":"Baumann","year":"1998","journal-title":"Trends Biochem. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2220\/biomedres.36.155","article-title":"Polymorphisms of canine BRCA2 BRC repeats affecting interaction with RAD51","volume":"36","author":"Ochiai","year":"2015","journal-title":"Biomed. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population","volume":"33","author":"Song","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and Ovarian Cancer Penetrance Estimates Derived from Germline Multiple-Gene Sequencing Results in Women","volume":"2017","author":"Kurian","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Gallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B.B., Kurian, A.W., Domchek, S.M., Garber, J., and Lancaster, J. (2020). Association of a Polygenic Risk Score with Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Netw. Open, 3.","DOI":"10.1001\/jamanetworkopen.2020.8501"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:43:11Z","timestamp":1760139791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":147,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23137481"],"URL":"https:\/\/doi.org\/10.3390\/ijms23137481","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}